Market Place
Sourcing Support
MIRA Reveals Phase I/IIa Trial Design and Site Selection
20 Nov 2024 //
ACCESSWIRE
MIRA’s Ketamir-2 Shows 60% Efficacy Over Gabapentin in Pain
28 Oct 2024 //
ACCESSWIRE
Mira Pharma`s Ketamir-2 Outperforms Gabapentin In Study
21 Oct 2024 //
ACCESSWIRE
MIRA Pharmaceuticals Advances Ketamir-2 Development
18 Sep 2024 //
ACCESSWIRE
MIRA Pharmaceuticals Targets Neuropathic Pain For Ketamir-2
11 Sep 2024 //
ACCESSWIRE
MIRA Pharma Achieves Full Reversal Of Neuropathic Pain With Oral Ketamir-2
26 Aug 2024 //
ACCESSWIRE
MIRA Pharma Prepares For Year-End IND Submission
19 Aug 2024 //
ACCESSWIRE
MIRA Pharma Unveils Ketamir-2`s Key Metabolite: Nor-Ketamir
12 Aug 2024 //
ACCESSWIRE
MIRA Pharma Discovers Ketamir-2`s Selective NMDA Binding Mechanism
25 Jul 2024 //
ACCESSWIRE
Mira Pharmaceuticals Announces Promising Results For MIRA-55
12 Jul 2024 //
ACCESSWIRE
MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile
24 Jun 2024 //
PR NEWSWIRE
Mira`s MIRA-55 Not Classified As Controlled Substance By DEA
30 May 2024 //
PR NEWSWIRE
MIRA Discusses MSK Cancer Pain Model Collaboration Using Ketamine Analog
21 May 2024 //
PR NEWSWIRE
Mira Announces Preclinical Results Advancing Ketamir-2 Towards IND Submission
02 Apr 2024 //
PR NEWSWIRE
MIRA Welcomes Dr. Itzchak, former Head of Pharmacology at Synthelabo, as CSA
21 Mar 2024 //
PR NEWSWIRE
MIRA Pharmaceuticals announces collaboration with Pharmaseed
08 Feb 2024 //
INDIAN PHARMA POST
MIRA Pharmaceuticals Provides Corporate Update
05 Feb 2024 //
PR NEWSWIRE
MIRA Releases Breakthrough Data from Artificial Intelligence Simulations
04 Dec 2023 //
PR NEWSWIRE
MIRA Pharma Announces Ketamir-2`s Oral Bioavailability Predicted to be 80%
29 Nov 2023 //
PRESS RELEASE
MIRA Pharma Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a
21 Nov 2023 //
PR NEWSWIRE
MIRA Pharmaceuticals To Host Shareholder Update Call
21 Nov 2023 //
PR NEWSWIRE
MIRA Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
20 Nov 2023 //
PR NEWSWIRE
MIRA Pharma Shows its Prescription Pill More Palatable and Potent Than Pot
18 Sep 2023 //
PR NEWSWIRE
MIRA and MZ Group Partner to Strengthen Investor Relations
05 Sep 2023 //
PR NEWSWIRE
MIRA to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit
31 Aug 2023 //
PR NEWSWIRE
MIRA Pharma to Ring the Nasdaq Opening Bell on Wednesday, August 9, 2023
09 Aug 2023 //
PR NEWSWIRE
MIRA Pharma Announces Closing of $8.9 Million Initial Public Offering
07 Aug 2023 //
PR NEWSWIRE
MIRA Pharma Announces Pricing of $8.9M Initial Public Offering & Nasdaq Listing
02 Aug 2023 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.